If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Retevmo ® (selpercatinib) capsules
40 mg, 80 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Does hepatic impairment affect Retevmo® (selpercatinib pharmacokinetic properties?
Selpercatinib dosing modifications are recommended for patients with severe hepatic impairment.
Effect of Hepatic Impairment on Selpercatinib Pharmacokinetic Properties
Close monitoring of patients with impaired hepatic function is important.1
Selpercatinib Dosing in Severe Hepatic Impairment
Patients with severe hepatic impairment should be dosed with 80 mg selpercatinib twice daily. In patients with severe hepatic impairment (Child-Pugh class C), the selpercatinib AUC0-INF increased by 77%.1
Selpercatinib Dosing in Mild and Moderate Hepatic Impairment
Hepatic Impairment Classifications
Hepatic Impairment Classification by Total Bilirubin and Aspartate Aminotransferase Values summarizes total bilirubin and aspartate aminotransferase values associated with hepatic impairment classifications.1
Hepatic Impairment Classification |
Associated Clinical Values |
Mild |
Total bilirubin ≤ ULN and AST > ULN, OR Total bilirubin > 1 to 1.5 times ULN and any AST |
Moderate |
Total bilirubin > 1.5 to 3 times ULN and any AST |
Severe |
Total bilirubin > 3 times ULN and any AST |
Abbreviations: AST = aspartate aminotransferase; ULN = upper limit of normal
Enclosed Prescribing Information
References
1Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: January 04, 2023